Lupin is currently trading at Rs. 709.40, up by 11.05 points or 1.58% from its previous closing of Rs. 698.35 on the BSE.
The scrip opened at Rs. 695.15 and has touched a high and low of Rs. 714.50 and Rs. 695.15 respectively. So far 23544 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 972.50 on 14-Dec-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 714.50 and Rs. 684.20 respectively. The current market cap of the company is Rs. 32119.43 crore.
The promoters holding in the company stood at 47.11%, while Institutions and Non-Institutions held 41.44% and 11.45% respectively.
The USFDA has inspected Lupin’s Nagpur Unit-2 injectable manufacturing facility from October 17, 2022 to October 29, 2022. The inspection was a Pre-Approval Inspection of the injectable facility.
The inspection closed with issuance of a Form-483 with five observations. The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the U.S.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
